Literature DB >> 3935467

Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B.

R E Heikkila, R C Duvoisin, J P Finberg, M B Youdim.   

Abstract

Two selective and potent inhibitors of monoamine oxidase (MAO) type B, namely AGN-1133 (N-methyl-N-propynyl-1-indanamine) and AGN-1135 (N-propynyl-1-indanamine), given to mice prior to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) protected against the neurotoxic effects of MPTP. For example, mice treated with these agents prior to MPTP, did not exhibit the decrement in the neostriatal content of dopamine and its metabolites normally seen after MPTP administration. These data lend further support to the concept that the oxidation of MPTP by MAO-B to its corresponding pyridinium analog, 1-methyl-4-phenyl-pyridinium (MPP+) is an important feature of the neurotoxic process.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3935467     DOI: 10.1016/0014-2999(85)90168-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

Review 1.  Disease modification in Parkinson's disease.

Authors:  Claire Henchcliffe; W Lawrence Severt
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

Review 2.  Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil.

Authors:  Moussa B H Youdim; Tamar Amit; Orit Bar-Am; Orly Weinreb; Mara Yogev-Falach
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

Review 3.  Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].

Authors:  M B Youdim; M Weinstock
Journal:  Cell Mol Neurobiol       Date:  2001-12       Impact factor: 5.046

Review 4.  Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway.

Authors:  Silvia A Mandel; Yotam Sagi; Tamar Amit
Journal:  Neurochem Res       Date:  2007-08-16       Impact factor: 3.996

Review 5.  Rasagiline: a review of its use in the management of Parkinson's disease.

Authors:  Vicki Oldfield; Gillian M Keating; Caroline M Perry
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs.

Authors:  Orly Weinreb; Silvia Mandel; Orit Bar-Am; Merav Yogev-Falach; Yael Avramovich-Tirosh; Tamar Amit; Moussa B H Youdim
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

7.  Intracerebroventricular administration of 1-methyl-4-phenylpyridinium ion in mice: effects of simultaneously administered nomifensine, deprenyl, and 1-t-butyl-4,4-diphenylpiperidine.

Authors:  W Mihatsch; H Russ; H Przuntek
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

8.  Adjunctive therapy in Parkinson's disease: the role of rasagiline.

Authors:  Kathryn D Gaines; Vanessa K Hinson
Journal:  Neuropsychiatr Dis Treat       Date:  2012-07-02       Impact factor: 2.570

9.  MAO-inhibitors in Parkinson's Disease.

Authors:  Peter Riederer; Gerd Laux
Journal:  Exp Neurobiol       Date:  2011-03-31       Impact factor: 3.261

10.  Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline.

Authors:  Moussa B H Youdim
Journal:  Exp Neurobiol       Date:  2013-03-31       Impact factor: 3.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.